WHITEHOUSE STATION, N.J. (AP) - New studies show that Merck's Gardasil vaccine protects most young women from cervical cancer and homosexual men from anal cancer.
The vaccine is designed to block four of the most common strains of the sexually transmitted human papilloma virus, or HPV.
Gardasil is already approved for preventing cervical cancer and genital warts in females aged 9 to 26, and for preventing genital warts in males aged 9 to 26.
One of the new studies shows Gardasil is about 89 percent effective in blocking cervical cancer, genital warts and lingering HPV infections in women aged 24 to 45. The other shows it is about 77 percent effective in blocking anal cancer and precancerous lesions in homosexual men.
Merck will seek approval to sell the vaccine for those uses. It funded both studies.
Web Search powered by YAHOO!
|
LifestylesLifestyles
Merck: Studies boost Gardasil for new uses
WHITEHOUSE STATION, N.J. (AP) - New studies show that Merck's Gardasil vaccine protects most young women from cervical cancer and homosexual men from anal cancer.
By:
|
WNCT
Published: February 17, 2010
Published: February 17, 2010
Email
Facebook
Google
Twitter
Favorites
MoreAdvertisement
View More:
Anal Cancer,
Cervical Cancer,
Gardasil,
Genital Warts,
Health_Medical_Pharma,
Hpv,
Hpv Infections,
Human Papilloma Virus,
Merck,
New Jersey,
Whitehouse Station
Not what you're looking for? Try our quick search:
Reader Comments
*Facebook Account Required to Comment. If you are not already logged into Facebook, please click the comment button to do so.Deal of the Day
Advertisement
Interactive Radar
Advertisement
Featured Blogger
Reel Reviews
Updated: 02/10/2012
Nine On Your Side's Phillip Sayblack shares his take on the latest movie and dvd releases.
More Posts by Reel Reviews
Hot Topics on WNCT.com
Advertisement
Advertisement